Home  |  Contact

UniProtKB/Swiss-Prot Q8TD43: Variant p.Pro970Ser

Transient receptor potential cation channel subfamily M member 4
Gene: TRPM4
Variant information

Variant position:  970
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Proline (P) to Serine (S) at position 970 (P970S, p.Pro970Ser).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (P) to small size and polar (S)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In PFHB1B; incomplete right bundle-branch block.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.

Sequence information

Variant position:  970
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1214
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.




Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 1 – 1214 Transient receptor potential cation channel subfamily M member 4
Intramembrane 964 – 984 Pore-forming
Mutagenesis 977 – 977 Q -> E. Alters the monovalent cation permeability sequence and results in a pore with moderate Ca(2+) permeability.
Mutagenesis 981 – 981 E -> A. Results in a channel with normal permeability properties but with a reduced sensitivity to block by intracellular spermine.
Mutagenesis 982 – 982 D -> A. Results in a functional channel that exhibits extremely fast desensitization, possibly indicating destabilization of the pore.
Mutagenesis 984 – 984 D -> A. Results in a non-functional channel with a dominant negative phenotype.
Helix 968 – 972

Literature citations

Mutational spectrum in the Ca(2+) -activated cation channel gene TRPM4 in patients with cardiac conductance disturbances.
Stallmeyer B.; Zumhagen S.; Denjoy I.; Duthoit G.; Hebert J.L.; Ferrer X.; Maugenre S.; Schmitz W.; Kirchhefer U.; Schulze-Bahr E.; Guicheney P.; Schulze-Bahr E.;
Hum. Mutat. 33:109-117(2012)
Cited for: VARIANTS PFHB1B HIS-131; ARG-293; THR-432; SER-582; HIS-790; ASP-844; ARG-914 AND SER-970; VARIANTS THR-101; CYS-103; HIS-252; LYS-487 DEL; ALA-561; ARG-854 AND LEU-1204;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.